# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $11 to $13.
Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $12 to $15.
B. Riley Securities analyst Anderson Schock initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price ...
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $11.
Keybanc analyst Paul Knight upgrades Exagen (NASDAQ:XGN) from Sector Weight to Overweight and maintains the price target fro...